MetaVia (MTVA) Shares Outstanding (2015 - 2026)
MetaVia's (MTVA) quarterly Shares Outstanding (Entity) came in at $1.8 million in Q4 2025, up 124.92% YoY from $785190.0 in Q4 2024, and down 19.78% on a QoQ basis from $2.2 million in Q3 2025.
MetaVia (MTVA) Shares Outstanding (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Shares Outstanding (Entity) data on file, last reported at $1.8 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 124.92% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (up 124.92% YoY) and the FY2025 annual result came in at $1.8 million, up 124.92% from the prior year.
- Shares Outstanding (Entity) slipped to $1.8 million in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.2 million in Q3 2025 to a low of $8397.0 in Q1 2021.
- A 5-year average of $526172.2 and a median of $441352.0 in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) surged 4454.51% — and 2024, when it slipped 3.02%.
- Tracing MTVA's Shares Outstanding (Entity) over 5 years: stood at $10098.0 in 2021, then soared by 189.62% to $29246.0 in 2022, then surged by 1425.01% to $446004.0 in 2023, then surged by 76.05% to $785190.0 in 2024, then surged by 124.92% to $1.8 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $1.8 million (Q4 2025), $2.2 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 5.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 933,119.00 |
| Dec 31, 2024 | 705,201.00 |
| Sep 30, 2024 | 928,563.00 |
| Jun 30, 2024 | 493,542.00 |
| Mar 31, 2024 | 462,678.00 |
| Dec 31, 2023 | 461,014.00 |
| Sep 30, 2023 | 461,443.00 |
| Jun 30, 2023 | 459,914.00 |
| Mar 31, 2023 | 459,914.00 |
| Dec 31, 2022 | 29,246.00 |
| Sep 30, 2022 | 10,099.00 |
| Jun 30, 2022 | 10,098.00 |
| Mar 31, 2022 | 10,098.00 |
| Dec 31, 2021 | 8,766.00 |
| Sep 30, 2021 | 8,441.00 |
| Jun 30, 2021 | 8,408.00 |